Registry for patients with rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis receiving biologics

Korean College of Rheumatology Biologics and Targeted Therapy Registry

This study is collecting information from patients with rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis who are using biologic treatments to see how these medications work in real life.

Quick facts

• Study type: Observational
• Enrollment: 10000 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Seoul National University Hospital (other)
• Locations: 1 site (Seoul)
• Trial ID: NCT01965132 on ClinicalTrials.gov

What this trial studies

This registry collects data on patients with rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis who are treated with biologics or targeted synthetic DMARDs in Korea. It is a multi-center, prospective, observational program that reflects real-world treatment practices without imposing experimental interventions. Physicians will determine treatment plans, and data will be gathered during routine clinical visits, ensuring that the registry captures the safety profiles of these therapies in everyday use.

Who should consider this trial

Good fit: Ideal candidates include patients diagnosed with rheumatoid arthritis, ankylosing spondylitis, or psoriatic arthritis who require treatment with biologics or targeted synthetic DMARDs.

Not a fit: Patients who are already on biologics or targeted synthetic DMARDs at the time of screening will not benefit from this registry.

Why it matters

Potential benefit: If successful, this registry could provide valuable insights into the safety and effectiveness of biologics and targeted synthetic DMARDs for patients with rheumatic diseases.

How similar studies have performed: Other observational registries have shown success in capturing real-world data and improving understanding of treatment outcomes in similar patient populations.

Eligibility criteria

Inclusion Criteria:

* Patients diagnosed with RA, AS or PsA
* RA deemed by their rheumatologist to require treatment with a biologic or targeted synthetic DMARDs or a conventional DMARD(s)
* AS or PsA patients who are to initiate, restart or switch to a biologic agent or a targeted synthetic DMARD
* Patients who provide a written consent of participating in this registry (data collection and review).

Exclusion Criteria:

* RA, AS, PsA patients who are already on biologics or targeted synthetic DMARDs upon screening

Where this trial is running

Seoul

• Seoul Metropolitan Government-Seoul National University Boramae Medical Center — Seoul, South Korea (RECRUITING)

Study contacts

• Principal investigator: Eun Yeong Lee, MD — Seoul National University Hospital
• Study coordinator: Kichul Shin, MD

Conditions: Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Rheumatiod Arhthritis, Ankylosing spondylitis, Psoriatic arthritis, Biologic agents, Cohort studies